| Literature DB >> 33414501 |
Maged M Harraz1, Prasun Guha1, Evan R Semenza1, Adarsha P Malla1, In Guk Kang1, Young Jun Song1, Luke Reilly1, Isaac Treisman1, Pedro Cortés1, Mark A Coggiano2, Vijayabhaskar Veeravalli3, Rana Rais3, Gianluigi Tanda2, Solomon H Snyder4,5,6.
1. The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
2. Medication Development Program, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, 21224, USA.
3. Department of Neurology and Johns Hopkins Drug Discovery (JHDD) Program, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
4. The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. ssnyder@jhmi.edu.
5. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. ssnyder@jhmi.edu.
6. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. ssnyder@jhmi.edu.
Abstract
Entities:
Mesh:
Animals
Autophagy
Cocaine/pharmacology
Dopamine Plasma Membrane Transport Proteins/metabolism
Dopamine Uptake Inhibitors/pharmacology
Mice
Nucleus Accumbens/metabolism
Substances:
Dopamine Plasma Membrane Transport Proteins
Dopamine Uptake Inhibitors
Cocaine
Year: 2021 PMID: 33414501 PMCID: PMC8625012 DOI: 10.1038/s41380-020-00978-y
Source DB: PubMed Journal: Mol Psychiatry ISSN: 1359-4184 Impact factor: 15.992